
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deudextromethorphan Hydrobromide,Deudextromethorphan HBr,Quinidine sulphate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Otsuka America Pharmaceutical, Inc.
Deal Size : Undisclosed
Deal Type : Merger
Details : Avanir and Otsuka have always shared a deep commitment to advancing solutions that improve the lives of patients by Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Deudextromethorphan Hydrobromide,Deudextromethorphan HBr,Quinidine sulphate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Otsuka America Pharmaceutical, Inc.
Deal Size : Undisclosed
Deal Type : Merger
